These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36293222)
41. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066 [TBL] [Abstract][Full Text] [Related]
42. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment. Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872 [TBL] [Abstract][Full Text] [Related]
43. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
44. Long-Term Efficacy, Survival, and Safety of [ Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192 [No Abstract] [Full Text] [Related]
45. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT. Makis W; McCann K; McEwan AJ Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505 [TBL] [Abstract][Full Text] [Related]
46. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT? Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704 [TBL] [Abstract][Full Text] [Related]
47. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based Sundlöv A; Gleisner KS; Tennvall J; Ljungberg M; Warfvinge CF; Holgersson K; Hallqvist A; Bernhardt P; Svensson J Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3830-3840. PubMed ID: 35451612 [TBL] [Abstract][Full Text] [Related]
53. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]
54. Relevance of radiobiological concepts in radionuclide therapy of cancer. Kumar C; Shetake N; Desai S; Kumar A; Samuel G; Pandey BN Int J Radiat Biol; 2016; 92(4):173-86. PubMed ID: 26917443 [TBL] [Abstract][Full Text] [Related]
55. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072 [TBL] [Abstract][Full Text] [Related]
56. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115 [TBL] [Abstract][Full Text] [Related]
57. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. Ranade R; Basu S J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166 [TBL] [Abstract][Full Text] [Related]
58. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Haider M; Das S; Al-Toubah T; Pelle E; El-Haddad G; Strosberg J Endocr Relat Cancer; 2021 Mar; 28(3):R81-R93. PubMed ID: 33608483 [TBL] [Abstract][Full Text] [Related]
59. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608 [TBL] [Abstract][Full Text] [Related]